Buchumschlag

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Jessica D. Lee, Konstantinos Papamichael, Lauren T. Grinspan, Adam S. Cheifetz, Melissa Spiel, Tatyana Kushner, Loren G. Rabinowitz
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
von: Jessica D. Lee, et al.
Veröffentlicht: (2025)

Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
von: Konstantinos Papamichael, et al.
Veröffentlicht: (2024)

Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
von: Lynna Chen, et al.
Veröffentlicht: (2025)

Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease
von: Catherine Z. Tang, et al.
Veröffentlicht: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease
von: Jeli Mendoza, et al.
Veröffentlicht: (2024)

Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation
von: Simone Chin, et al.
Veröffentlicht: (2025)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
von: Purab Patel, et al.
Veröffentlicht: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
von: Matthew D. Coates, et al.
Veröffentlicht: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
von: Marco Vincenzo Lenti, et al.
Veröffentlicht: (2025)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
von: Suprabhat Giri, et al.
Veröffentlicht: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease?
von: Agnes Hiu Yan Ho, et al.
Veröffentlicht: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
von: Chang Liu, et al.
Veröffentlicht: (2026)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
von: Joyce Wing Yan Mak
Veröffentlicht: (2025)

Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
von: Uma Mahadevan, et al.
Veröffentlicht: (2025)

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
von: Quinn Goddard, et al.
Veröffentlicht: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease
von: Erik Lundqvist, et al.
Veröffentlicht: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
von: A. B. Fons, et al.
Veröffentlicht: (2026)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
von: Fai Fai Ho, et al.
Veröffentlicht: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues
von: Stephanie Gold, et al.
Veröffentlicht: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
von: Suprabhat Giri, et al.
Veröffentlicht: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
von: Bharati Kochar, et al.
Veröffentlicht: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
von: Nicholas Clark, et al.
Veröffentlicht: (2025)

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease
von: Benedikt Simbrunner, et al.
Veröffentlicht: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
von: Aurelien Amiot, et al.
Veröffentlicht: (2025)

Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy
von: Shamim Joudaki, et al.
Veröffentlicht: (2025)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
von: Dhruv Ahuja, et al.
Veröffentlicht: (2025)

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity
von: Brigida Barberio, et al.
Veröffentlicht: (2026)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
von: Jessica A. Fitzpatrick, et al.
Veröffentlicht: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
von: Cristina Rubín de Célix, et al.
Veröffentlicht: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
von: Cong Dai, et al.
Veröffentlicht: (2024)

Editorial: Shooting in the Dark—The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease
von: Jane Lim, et al.
Veröffentlicht: (2025)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
von: Muhammad Osama, et al.
Veröffentlicht: (2024)

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease
von: Wah Loong Chan, et al.
Veröffentlicht: (2024)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
von: Liang Jiao, et al.
Veröffentlicht: (2026)

Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort
von: Christy Riggott, et al.
Veröffentlicht: (2025)

Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study
von: Christy Riggott, et al.
Veröffentlicht: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
von: Jee‐Fu Huang, et al.
Veröffentlicht: (2026)

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death
von: Mathias Jachs, et al.
Veröffentlicht: (2025)

Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study
von: Ronen Stein, et al.
Veröffentlicht: (2025)